Royalty Net Income From Continuing Ops from 2010 to 2026
| RPRX Stock | USD 44.65 0.55 1.25% |
Net Income From Continuing Ops | First Reported 2016-12-31 | Previous Quarter 90.6 M | Current Value 444.2 M | Quarterly Volatility 360.5 M |
Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 272.3 M, Total Revenue of 2.7 B or Research Development of 2.2 M, as well as many indicators such as Price To Sales Ratio of 10.18, Dividend Yield of 0.0363 or PTB Ratio of 1.79. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
Royalty | Net Income From Continuing Ops | Build AI portfolio with Royalty Stock |
The evolution of Net Income From Continuing Ops for Royalty Pharma Plc provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Royalty Pharma compares to historical norms and industry peers.
Latest Royalty Pharma's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Royalty Pharma Plc over the last few years. It is Royalty Pharma's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Royalty Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 822,262,709 | |
| Coefficient Of Variation | 102.82 | |
| Mean Deviation | 771,432,667 | |
| Median | 1,143,470,100 | |
| Standard Deviation | 845,454,503 | |
| Sample Variance | 714793.3T | |
| Range | 2.5B | |
| R-Value | 0.68 | |
| Mean Square Error | 407851.3T | |
| R-Squared | 0.47 | |
| Significance | 0 | |
| Slope | 114,177,832 | |
| Total Sum of Squares | 11436693.1T |
Royalty Net Income From Continuing Ops History
About Royalty Pharma Financial Statements
Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 1.5 B | 1.1 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.